Impact of the RTS,S malaria vaccine candidate on naturally acquired antibody responses to multiple asexual blood stage antigens

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Campo, Joseph J ^a,b   Dobaño, Carlota ^a,b   Sacarlal, Jahit ^b   Guinovart, Caterina ^a,b   Mayor, Alfredo ^a,b   Angov, Evelina ^c   Dutta, Sheetij ^c   Chitnis, Chetan ^d   Macete, Eusebio ^b   Aponte, John J ^a,b   Alonso, Pedro L ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Ministérioda Saúde   (Mozambique)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^d INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMA 1 ANTIGEN; ANTIGEN; DBL ALPHA ANTIGEN; EBA 175 ANTIGEN; IMMUNOGLOBULIN G; MALARIA VACCINE; MSP 1 42 ANTIGEN; PARASITE ANTIGEN; RTS,S AS02 MALARIA VACCINE; UNCLASSIFIED DRUG; VARIANT SURFACE ANTIGEN; PROTOZOON ANTIBODY;

AGE; ANTIBODY RESPONSE; ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; VACCINATION; ADAPTIVE IMMUNITY; ANIMAL; ANTIBODY PRODUCTION; BLOOD; CASE CONTROL STUDY; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIFE CYCLE STAGE; MALARIA FALCIPARUM; MULTIVARIATE ANALYSIS; PARASITOLOGY; PLASMODIUM FALCIPARUM; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL;

ADAPTIVE IMMUNITY; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIBODY FORMATION; ANTIGENS, PROTOZOAN; CASE-CONTROL STUDIES; HUMANS; IMMUNOGLOBULIN G; LIFE CYCLE STAGES; LINEAR MODELS; MALARIA VACCINES; MALARIA, FALCIPARUM; MULTIVARIATE ANALYSIS; PLASMODIUM FALCIPARUM; PROPORTIONAL HAZARDS MODELS; VACCINATION;

EID: 80053949037     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025779     Document Type: Article

References (49)

1. Cohen J, Nussenzweig V, Nussenzweig R, Vekemans J, Leach A, (2010) From the circumsporozoite protein to the RTS, S/AS candidate vaccine. Human Vaccines 6: 90-6.
2. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, et al. (1997) A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. The New England Journal of Medicine 336: 86-91.
3. Garçon N, Chomez P, Van Mechelen M, (2007) GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Review of Vaccines 6: 723-39.
4. Moorthy VS, Ballou WR, (2009) Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malaria Journal 8: 312.
5. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, et al. (2009) Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. The Journal of Infectious Diseases 200: 337-46.
6. Casares S, Brumeanu T-D, Richie TL, (2010) The RTS,S malaria vaccine. Vaccine 28: 4880-94.
7. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2004) Efficacy of the RTS, S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. The Lancet 364: 1411-1420.
8. Aponte JJ, Aide P, Renom M, Mandomando I, Bassat Q, et al. (2007) Safety of the RTS, S/AS02D candidate malaria vaccine in infants living in a highly endemic area of Mozambique: a double blind randomised controlled phase I/IIb trial. The Lancet 370: 1543-1551.
9. Bejon P, Lusingu J, Olotu A, Leach A, Lievens M, et al. (2008) Efficacy of RTS,S/AS01E vaccine against malaria in children 5 to 17 months of age. The New England Journal of Medicine 359: 2521-32.
10. Aide P, Aponte JJ, Renom M, Nhampossa T, Sacarlal J, et al. (2010) Safety, immunogenicity and duration of protection of the RTS,S/AS02(D) malaria vaccine: one year follow-up of a randomized controlled phase I/IIb trial. PLoS One 5: e13838.
11. Olotu A, Lusingu J, Leach A, Lievens M, Vekemans J, et al. (2011) Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5-17 months in Kenya and Tanzania: a randomised controlled trial. The Lancet Infectious Diseases 11: 102-9.
12. Aide P, Dobaño C, Sacarlal J, Aponte JJ, Mandomando I, et al. (2011) Four year immunogenicity of the RTS,S/AS02(A) malaria vaccine in Mozambican children during a phase IIb trial. Vaccine. [Epub ahead of print].
13. Sacarlal J, Aide P, Aponte JJ, Renom M, Leach A, et al. (2009) Long-term safety and efficacy of the RTS,S/AS02A malaria vaccine in Mozambican children. The Journal of Infectious Diseases 200: 329-36.
14. Bojang KA, Milligan PJM, Pinder M, Vigneron L, Alloueche A, et al. (2001) Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. The Lancet 358: 1927-1934.
15. Stoute JA, Kester KE, Krzych U, Wellde BT, Hall T, et al. (1998) Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. The Journal of Infectious Diseases 178: 1139-44.
16. Kester KE, McKinney DA, Tornieporth N, Ockenhouse CF, Heppner DG, et al. (2001) Efficacy of recombinant circumsporozoite protein vaccine regimens against experimental Plasmodium falciparum malaria. The Journal of Infectious Diseases 183: 640-7.
17. Schellenberg D, Menendez C, Aponte JJ, Kahigwa E, Tanner M, et al. (2005) Intermittent preventive antimalarial treatment for Tanzanian infants: follow-up to age 2 years of a randomised, placebo-controlled trial. The Lancet 365: 1481-1483.
18. Sutherland CJ, Drakeley CJ, Schellenberg D, (2007) How is childhood development of immunity to Plasmodium falciparum enhanced by certain antimalarial interventions? Malaria Journal 6: 161.
19. Guinovart C, Aponte JJ, Sacarlal J, Aide P, Leach A, et al. (2009) Insights into long-lasting protection induced by RTS,S/AS02A malaria vaccine: further results from a phase IIb trial in Mozambican children. PLoS One 4: e5165.
20. Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat Q, et al. (2008) Safety of the RTS,S/AS02A malaria vaccine in Mozambican children during a Phase IIb trial. Vaccine 26: 174-84.
21. Kocken CHM, Withers-Martinez C, Dubbeld MA, Wel A van der, Hackett F, et al. (2002) High-level expression of the malaria blood-stage vaccine candidate Plasmodium falciparum apical membrane antigen 1 and induction of antibodies that inhibit erythrocyte invasion. Infection and Immunity 70: 4471-6.
22. Angov E, (2003) Development and pre-clinical analysis of a Plasmodium falciparum Merozoite Surface Protein-142 malaria vaccine. Molecular and Biochemical Parasitology 128: 195-204.
23. Angov E, Hillier CJ, Kincaid RL, Lyon JA, (2008) Heterologous protein expression is enhanced by harmonizing the codon usage frequencies of the target gene with those of the expression host. PLoS One 3: e2189.
24. Crompton PD, Pierce SK, Miller LH, (2010) Advances and challenges in malaria vaccine development. The Journal of Clinical Investigation 120: 4168-4178.
25. Mayor A, Rovira-Vallbona E, Srivastava A, Sharma SK, Pati SS, et al. (2009) Functional and immunological characterization of a Duffy binding-like alpha domain from Plasmodium falciparum erythrocyte membrane protein 1 that mediates rosetting. Infection and Immunity 77: 3857-63.
26. Sim BK, Chitnis CE, Wasniowska K, Hadley TJ, Miller LH, (1994) Receptor and ligand domains for invasion of erythrocytes by Plasmodium falciparum. Science 264: 1941-4.
27. Triglia T, Healer J, Caruana SR, Hodder AN, Anders RF, et al. (2000) Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Molecular Microbiology 38: 706-18.
28. Okenu DM, Riley EM, Bickle QD, Agomo PU, Barbosa A, et al. (2000) Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infection and Immunity 68: 5559-66.
29. Stanisic DI, Richards JS, McCallum FJ, Michon P, King CL, et al. (2009) Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infection and Immunity 77: 1165-74.
30. Richards JS, Stanisic DI, Fowkes FJI, Tavul L, Dabod E, et al. (2010) Association between Naturally Acquired Antibodies to Erythrocyte-Binding Antigens of Plasmodium falciparum and Protection from Malaria and High-Density Parasitemia. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 51: e50-60.
31. Alonso PL, Sacarlal J, Aponte JJ, Leach A, Macete E, et al. (2005) Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. The Lancet 366: 2012-2018.
32. Pandey KC, Singh S, Pattnaik P, Pillai CR, Pillai U, et al. (2002) Bacterially expressed and refolded receptor binding domain of Plasmodium falciparum EBA-175 elicits invasion inhibitory antibodies. Molecular and Biochemical Parasitology 123: 23-33.
33. Miura K, Orcutt AC, Muratova OV, Miller LH, Saul A, et al. (2008) Development and characterization of a standardized ELISA including a reference serum on each plate to detect antibodies induced by experimental malaria vaccines. Vaccine 26: 193-200.
34. Little JA, (2004) Comparison of Curve Fitting Models for Ligand Binding Assays. Chromatographia 59: S177-S181-S181.
35. Gottschalk PG, Dunn JR, (2005) The five-parameter logistic: a characterization and comparison with the four-parameter logistic. Analytical Biochemistry 343: 54-65.
36. Serra-Casas E, Menéndez C, Bardají A, Quintó L, Dobaño C, et al. (2010) The effect of intermittent preventive treatment during pregnancy on malarial antibodies depends on HIV status and is not associated with poor delivery outcomes. The Journal of Infectious Diseases 201: 123-31.
37. Vestergaard LS, Lusingu JP, Nielsen MA, Mmbando BP, Dodoo D, et al. (2008) Differences in human antibody reactivity to Plasmodium falciparum variant surface antigens are dependent on age and malaria transmission intensity in northeastern Tanzania. Infection and Immunity 76: 2706-14.
38. Reed GF, Meade BD, Steinhoff MC, (1995) The reverse cumulative distribution plot: a graphic method for exploratory analysis of antibody data. Pediatrics 96: 600-3.
39. Conway DJ, Cavanagh DR, Tanabe K, Roper C, Mikes ZS, et al. (2000) A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nature Medicine 6: 689-92.
40. Bejon P, Cook J, Bergmann-Leitner E, Olotu A, Lusingu J, et al. (2011) Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children. The Journal of Infectious Diseases 204: 9-18.
41. Drakeley CJ, Corran PH, Coleman PG, Tongren JE, McDonald SLR, et al. (2005) Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proceedings of the National Academy of Sciences of the United States of America 102: 5108-13.
42. Quelhas D, Puyol L, Quintó L, Serra-Casas E, Nhampossa T, et al. (2008) Impact of intermittent preventive treatment with sulfadoxine-pyrimethamine on antibody responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. Clinical and vaccine Immunology: CVI 15: 1282-91.
43. Greenhouse B, Ho B, Hubbard A, Njama-Meya D, Narum DL, et al. (2011) Antibodies to Plasmodium falciparum Antigens Predict a Higher Risk of Malaria But Protection From Symptoms Once Parasitemic. The Journal of Infectious Diseases 204: 19-26.
44. Aponte JJ, Menendez C, Schellenberg D, Kahigwa E, Mshinda H, et al. (2007) Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Medicine 4: e242.
45. Okech BA, Corran PH, Todd J, Joynson-Hicks A, Uthaipibull C, et al. (2004) Fine Specificity of Serum Antibodies to Plasmodium falciparum Merozoite Surface Protein, PfMSP-119, Predicts Protection from Malaria Infection and High-Density Parasitemia. Infection and Immunity 72: 1557-1567.
46. Ferreira MU, Kimura EAS, Souza JM de, Katzin AM, (1996) The Isotype Composition and Avidity of Naturally Acquired Anti-Plasmodium falciparum Antibodies: Differential Patterns in Clinically Immune Africans and Amazonian Patients. Am J Trop Med Hyg 55: 315-323.
47. Crompton PD, Kayala MA, Traore B, Kayentao K, Ongoiba A, et al. (2010) A prospective analysis of the Ab response to Plasmodium falciparum before and after a malaria season by protein microarray. Proceedings of the National Academy of Sciences of the United States of America 107: 6958-63.
48. Osier FHA, Fegan G, Polley SD, Murungi L, Verra F, et al. (2008) Breadth and magnitude of antibody responses to multiple Plasmodium falciparum merozoite antigens are associated with protection from clinical malaria. Infection and Immunity 76: 2240-8.
49. Cham GKK, Turner L, Kurtis JD, Mutabingwa T, Fried M, et al. (2010) Hierarchical, domain type-specific acquisition of antibodies to Plasmodium falciparum erythrocyte membrane protein 1 in Tanzanian children. Infection and Immunity 78: 4653-9.